Delivered as an oral presentation at the Triological Society Combined Sections Meeting, Miami, Florida, U.S.A., January 26–28, 2012.
Oromandibular dystonia: Long-term management with botulinum toxin
Article first published online: 5 OCT 2013
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.
Volume 123, Issue 12, pages 3078–3083, December 2013
How to Cite
Sinclair, C. F., Gurey, L. E. and Blitzer, A. (2013), Oromandibular dystonia: Long-term management with botulinum toxin. The Laryngoscope, 123: 3078–3083. doi: 10.1002/lary.23265
Dr. Blitzer has received funding from and is a consultant for Allergan, Inc., Merz Pharmaceuticals, and Revance. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
- Issue published online: 25 NOV 2013
- Article first published online: 5 OCT 2013
- Manuscript Accepted: 3 FEB 2012
- Manuscript Revised: 30 JAN 2012
- Manuscript Received: 12 JAN 2012
- Oromandibular dystonia;
- muscle dystonia;
- botulinum toxin;
- movement disorders
To review the long-term management of patients with oromandibular dystonia (OMD) treated using botulinum toxin.
Retrospective chart review at a clinical research center.
Between 1995 and 2011, 59 patients with a diagnosis of OMD were treated with botulinum toxin. Data were collected on patient demographics, disease characteristics, and long-term treatment outcomes. Differences in management between an earlier published series of the first 20 OMD patients treated with botulinum toxin at this center and subsequent patients were analyzed.
Patients were more commonly female (72% vs. 28%) with an average age at first botulinum treatment of 56.6 years. The median number of treatments was five (range, 1–35 treatments). Average time between treatments was 3.8 months (±5.2). Overall, 47.5%, had the jaw-closing form of OMD, which was associated with a preferential deviation to one side in 53.6%. These patients received initial injections to the masseter ± temporalis muscle; the external pterygoid was injected for associated lateral jaw deviation. Internal pterygoid injections were rarely used (3.4%). For the jaw-opening form, injections were initially administered to the external pterygoid, with the addition of anterior digastric for ongoing symptoms. When compared with patients in the older series, more patients since 1988 had treatments to the external pterygoid (P = .001) and anterior digastric (P = .006) in accordance with an increase in the diagnosis of jaw-opening OMD (P = .05).
Long-term management of OMD with botulinum toxin has minimal morbidity and is useful for all clinical forms. Injections can be titrated by dose and location to address the predominant muscle groups involved.
Level of Evidence: 4 Laryngoscope, 123:3078–3083, 2013